NCCN Clinical Practice Guidelines in Oncology recommend monitoring CML patient response to treatment with Imantinib by periodically measuring BCR-ABL levels.

Testing for JAK2 levels is recommended in the revised 2008 WHO guidelines diagnostic criteria for MPD.

Information provided from molecular assays for leukemias and other blood cancers can help you and your patients make more informed decisions. Ask for JAK2 and BCR-ABL testing from your local or reference laboratory.

For more information about the guidelines, visit http://na.ipsogen.com and select the section

for Healthcare Professionals.

IPSOGEN Inc.700 Canal Street, Stamford, CT 06902203.504.8585 • www.ipsogen.com

© 2010 IPSOGEN Inc. All rights reserved. NA_A061001JCOFor Research Use Only. Not for use in diagnostic procedures.

Remember to follow the clinical practice guidelines for

CML and MPD

B i o m a r k e r T e s T i n g r e c o m m e n d e d B y n c c n a n d W H o